Log In
Print
BCIQ
Print
Print this Print this
 

BAN2401

  Manage Alerts
Collapse Summary General Information
Company BioArctic Neuroscience AB
DescriptionHumanized conformational specific IgG1 mAb targeting the toxic beta amyloid protofibrils
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

Partner

Biogen Idec Inc.; Eisai Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today